The Use of Ketorolac in Surgical Neonates
| Status: | Completed |
|---|---|
| Conditions: | Post-Surgical Pain |
| Therapuetic Areas: | Musculoskeletal |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 1/6/2019 |
| Start Date: | July 2012 |
| End Date: | December 31, 2018 |
The general purpose of this study is to characterize the safety profile of ketorolac in
infants age 0-3 months. Our hypothesis is that ketorolac is safe in neonates, and effective
in controlling pain with less narcotic administration required. Ketorolac 0.5mg/kg
intravenously every 8 hrs for 72hrs will be administered versus an equivalent volume of 0.9%
normal saline as placebo.
Primary: The primary purpose of this study is to compare bleeding events in neonates who
receive ketorolac and those who do not receive ketorolac. The investigators hypothesize that
ketorolac is safe and effective in infants > 37wks gestation and at least one week of age.
Secondary: The investigators intend to evaluate daily creatinine levels, pain scores, urine
output per shift, platelet counts, hemoglobin levels, number of days on the ventilator,
amount of narcotic administered, blood pressure, and reintubation events on all patients in
this study as secondary study points.
infants age 0-3 months. Our hypothesis is that ketorolac is safe in neonates, and effective
in controlling pain with less narcotic administration required. Ketorolac 0.5mg/kg
intravenously every 8 hrs for 72hrs will be administered versus an equivalent volume of 0.9%
normal saline as placebo.
Primary: The primary purpose of this study is to compare bleeding events in neonates who
receive ketorolac and those who do not receive ketorolac. The investigators hypothesize that
ketorolac is safe and effective in infants > 37wks gestation and at least one week of age.
Secondary: The investigators intend to evaluate daily creatinine levels, pain scores, urine
output per shift, platelet counts, hemoglobin levels, number of days on the ventilator,
amount of narcotic administered, blood pressure, and reintubation events on all patients in
this study as secondary study points.
This is a Phase II, single center, randomized controlled pilot study. Hospitalized patients
one week of age to 3 months of age who undergo an abdominal surgical procedure within the
moderate or severe degree of pain category (see attached Table 1: postoperative pain
categories) will be randomized to receive standard pain management regimens plus placebo
(0.9% saline of equivalent volume) or ketorolac 0.5mg IV q8h x 72h plus standard pain
management regimens. The postoperative management will be unchanged and at the discretion of
the attending surgeon, as appropriate for the surgical procedure. The patients will be
followed for 5 days, or 48hrs from the end of ketorolac therapy for primary and secondary
endpoints.
one week of age to 3 months of age who undergo an abdominal surgical procedure within the
moderate or severe degree of pain category (see attached Table 1: postoperative pain
categories) will be randomized to receive standard pain management regimens plus placebo
(0.9% saline of equivalent volume) or ketorolac 0.5mg IV q8h x 72h plus standard pain
management regimens. The postoperative management will be unchanged and at the discretion of
the attending surgeon, as appropriate for the surgical procedure. The patients will be
followed for 5 days, or 48hrs from the end of ketorolac therapy for primary and secondary
endpoints.
Inclusion Criteria:
1. Infants gestational age > 37 weeks and greater than or equal to one week of age to 3
months of age
2. Infants who are undergoing a surgical procedure on the abdomen
3. the parent or guardian has given informed consent.
Exclusion Criteria:
1. Gestational age < 37 weeks
2. Age less than one week or greater than 3 months of age
3. Known renal disease/dysplastic kidneys
4. Serum Creatinine > 0.4
5. Patients who have rising creatinine levels the day prior to surgery (increase of at
least 1.5-fold from baseline)
6. Patients who are currently receiving other potentially renal toxic drugs or drugs that
may interfere with hemostatic pathways as part of their clinical care (including but
not limited to furosemide, hydrochlorothiazide, vancomycin, gentamicin, aspirin, tpa
[except for use of thrombosed central venous catheters], enalapril, systemic heparin
[except for use in central venous catheter flushes])
7. Patients who undergo nephrectomy
8. Patients with necrotizing enterocolitis
9. Patients with a hemoglobin value < 10g/dL
10. Recent (within 3 months) GI bleeding, ulceration, and/or perforation
11. Platelet count < 50,000
12. Ongoing disseminated intravascular coagulation or history of intraventricular
hemorrhage
13. Recent (within 2 weeks) use or current use of other nonsteroidal anti-inflammatory
drugs (NSAIDS) besides aspirin (ASA)
14. Allergy to ASA or other NSAIDS
We found this trial at
1
site
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
Click here to add this to my saved trials
